Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Recap: WBCT Society Scientific Meeting

The Weight-Bearing CT Society held its latest Scientific Meeting in Las Vegas this past March during the AAOS 2019 conference. Co-sponsored by CurveBeam, the Scientific Meeting featured an education-packed agenda to discuss the revolutionary transformation weight-bearing technology is having on the imaging industry. First to present was Dr. Alexej Barg, MD, a University of Utah…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

The Weight-Bearing CT Society held its latest Scientific Meeting in Las Vegas this past March during the AAOS 2019 conference. Co-sponsored by CurveBeam, the Scientific Meeting featured an education-packed agenda to discuss the revolutionary transformation weight-bearing technology is having on the imaging industry.

First to present was Dr. Alexej Barg, MD, a University of Utah orthopedic surgeon who also served as the moderator for this event. In his presentation discussing imaging of patients with syndesmosis instability, Dr. Barg explained that conventional non-weight-bearing radiograph imaging cannot predict syndesmotic injuries reliably. And while MRI’s demonstrate sensitivity and specificity of nearly 100%, correlating patient complaints with MRI findings can be difficult. Further, although CT technology surpasses conventional imaging methods when 3D MRI or CT imaging is transferred to 2D, there is a substantial loss of information. However, the torque applied in the natural standing position offered higher contrast and spatial resolution of alignment and degeneration, providing a significant advantage in the accuracy of diagnosing syndesmotic injuries.

Dr. Pablo Wagner, MD, of Clinica Alemana in Chile then took the stage for a presentation titled “WBCT for Assessment of Metatarsal Rotation”. Crediting his brother, Emilio Wagner, MD, for his work with hallux valgus patients, Dr. Wagner explained that metatarsal condyles are visible laterally if pronated, of which 87 percent of hallux valgus cases are. If not corrected, metatarsal pronation will result in worse clinical outcomes and higher deformity relapse rates due to the soft tissue balance lateral to the medical ray axis. However, when compared to challenging, unreliable weight-bearing axial sesamoid views and more useful AP foot weight-bearing views on plan X-Ray, weight-bearing CT scans are the gold standard in quantifying metatarsal rotations.

Following Dr. Wagner, Dr. Cesar de Cesar Netto, MD, Ph.D., discussed “WBCT in Patients with AAFD”. While some symptoms or pain are experienced in patients with Adult-Acquired Flatfoot Deformity, it can be difficult knowing when to be more aggressive in treatment to prevent foot collapse. In a study of 55 male and female patients with stage II AAFD, multiple weight bearing CBCT and MRI variables related to the severity of the deformity were evaluated. Weight-bearing CBCT was found to provide more reliability in predicting patients at high risk for foot collapse.

Dr. Arne Burssens, MD, of the Univesity Hospital of Ghent then deliberated on the “Hidden Aspects of a Medializing Calcaneus Osteotomy Revealed by a WBCT”. Difficult to assess via 2D plain radiographic technology, there is a significant difference when assessing MCO in AAFD using weight-bearing imaging versus non-weight-bearing, offering substantial detail to improve understanding with a higher rate of reliability.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512